Sandu Pharmaceuticals Board of Directors
Get the latest insights into the leadership at Sandu Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Umesh B Sandu | Executive Director |
| Mr. Shashank B Sandu | Non Exe.Non Ind.Director |
| Dr.(Mrs.) Shubhada P Sandu | Non Exe.Non Ind.Director |
| Mr. Ajit R Kantak | Ind. Non-Executive Director |
| Mr. Balram Viswanathan | Ind. Non-Executive Director |
Sandu Pharmaceuticals Share price
SANDUPHQ
48.01
0.01 (0.02%)Last updated on 3 Sep, 2025 | 15:25 IST
BUYSELL
Today's High
49.00
Today's Low
48.00
52 Week Low
43.75
52 Week High
69.50
The current prices are delayed, login to your account for live prices
LoginSandu Pharmaceuticals FAQs
The board at Sandu Pharmaceuticals consists of experienced professionals, including Mr. Umesh B Sandu , Mr. Shashank B Sandu , and others, overseeing the company’s strategic and corporate governance.
Directors at Sandu Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Umesh B Sandu is the current chairman at Sandu Pharmaceuticals.
Executive directors at Sandu Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Sandu Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Sandu Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.